# Efficacy and Safety of PARPi to Treat Pancreatic Cancer

> **NCT02511223** · PHASE2 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 24 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** OLAPARIB

## Key facts

- **NCT ID:** NCT02511223
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2021-04-18
- **Final completion:** 2021-04-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511223, "Efficacy and Safety of PARPi to Treat Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02511223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*